



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



YK-029A

Cat. No.:	HY-155537
CAS No.:	2064269-82-3
Molecular Formula:	C ₂₇ H ₃₂ N ₈ O ₂
Molecular Weight:	500.6
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (199.76 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		1.9976 mL	9.9880 mL	19.9760 mL
		5 mM		0.3995 mL	1.9976 mL	3.9952 mL
		10 mM		0.1998 mL	0.9988 mL	1.9976 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (4.99 mM); Clear solution; Need ultrasonic					
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (4.99 mM); Clear solution; Need ultrasonic					

BIOLOGICAL ACTIVITY

Description	YK-029A is an orally active inhibitor of mutant EGFR targeting to both the T790M mutations (EGFR ^{T790M}) and exon 20 insertion of EGFR (EGFR ^{ex20ins}). YK-029A exhibits significant antitumor activity and results tumor regression in EGFR ^{ex20ins} -driven PDX models ^[1] .
IC ₅₀ & Target	EGFR ^{T790M} , EGFR ^{ex20ins} ^[1]

REFERENCES

[1]. Liu B, et al. Discovery of YK-029A, a novel mutant EGFR inhibitor targeting both T790 M and exon 20 insertion mutations, as a treatment for NSCLC. Eur J Med Chem. 2023 Oct 5;258:115590.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA